Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AMBUSH trial

<< Previous

Bullboard Posts

Next >>

Post by Quentin30on Feb 03, 2023 8:36pm

431 Views

Post# 35266335

AMBUSH trial

Is ONCY up to its old tricks of finding yet another cul-de-sac Phase I trial... this time its a phase Ib/2 study of std doses of Bortezomib and Pembrolizumab + Pelareorep for patients with relapsed multiple myeloma. Primary study completion date of Oct 2025... ah, so reassuring to be back to Phase I studies again... I wonder if they will find it to be safe and well tolerated, with a hint of efficacy on 1 patient..?

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?